Libra Therapeutics is a biotechnology company focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases. The company is advancing three distinct and novel preclinical small molecule programs designed to increase autophagy and decrease production of neurotoxic protein aggregates. Libra Therapeutics was founded to capitalize on proprietary technologies and therapeutic assets from Axxam, a leading discovery research company.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/23/20 | $29,000,000 | Series A |
Boehringer Ingelheim Venture Fund Dolby Family Ventures Epidarex Capital Sante Ventures Sixty Degree Capital Yonjin Venture | undisclosed |
